Breast Cancer Cell Mediated Apoptosis - A. Abd-Rabou, Ahmed;M. Abd El-Salam, Nagwa
49,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
25 °P sammeln
  • Broschiertes Buch

Breast cancer is one of the main causes of mortality globally and the available chemotherapy faced the obstacle of chemoresistance. Thus, providing a protein that is initially described to selectively trigger extrinsic and intrinsic apoptosis in breast cancer is very essential. This protein and cellular cytokine called "tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)". In the current book, we discussed some interesting topics including; Breast Cancer Biology, TRAIL combination therapy and apoptosis, Mechanism of Anticancer activity of Thymoquinone (TQ), as well as Apoptosis…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Breast cancer is one of the main causes of mortality globally and the available chemotherapy faced the obstacle of chemoresistance. Thus, providing a protein that is initially described to selectively trigger extrinsic and intrinsic apoptosis in breast cancer is very essential. This protein and cellular cytokine called "tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)". In the current book, we discussed some interesting topics including; Breast Cancer Biology, TRAIL combination therapy and apoptosis, Mechanism of Anticancer activity of Thymoquinone (TQ), as well as Apoptosis induction and cell cycle arrest. The synergistic influence of TRAIL combination with other therapies could provide a plus advantage in induction apoptosis-mediated DR5 receptor connection, which in turn helps in overcoming breast cancer resistance.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
La professoressa Hanaa H. Ahmed, direttrice del Laboratorio Cellule Staminali, Centro di Eccellenza per le Scienze Avanzate, NRC, aveva una grande esperienza nella terapia con le cellule staminali con un indice H=25. Il Professore associato Ahmed A. Abd-Rabou ha maturato un'accurata esperienza in nanomedicina presso l'Albany College of Pharmacy and Health Sciences (USA) e l'INSERM (Francia) con un H-index=17.